High materiality7/10
Definium Therapeutics price target raised to $60 from $38 at Canaccord
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity raises Definium Therapeutics (DFTX) price target to $60 from $38; current price around $38.11.
- Target raised to $60 from $38; Canaccord Genuity.
- Current price around $38.11; bullish target uplift.
Key facts
- 01
Target: $60
- 02
Posted price: $38.11
- 03
Analyst firm: Canaccord Genuity
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.